ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

NBRV Nabriva Therapeutics PLC

1.42
0.00 (0.00%)
03 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Nabriva Therapeutics PLC NASDAQ:NBRV NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 1.42 1.41 1.47 0 01:00:00

Report of Foreign Issuer (6-k)

22/11/2016 2:00pm

Edgar (US Regulatory)


 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM 6-K

 


 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of November 2016

 

Commission File Number 001-37558

 


 

NABRIVA THERAPEUTICS AG

(Translation of registrant’s name into English)

 


 

Leberstrasse 20

1110 Vienna, Austria

(Address of principal executive office)

 


 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

FORM 20-F  x             FORM 40-F  o

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):   o

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):   o

 

 

 



 

Announcement of Change of Record Date for Planned Rights Offering

 

On November 22, 2016, Nabriva Therapeutics AG issued a press release announcing that it had changed the record date for its previously announced planned rights offering from November 22, 2016, to November 29, 2016. A copy of the press release is attached hereto as Exhibit 99.1. The information contained in this Form 6-K and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

NABRIVA THERAPEUTICS AG

 

 

 

 

By:

/s/ Colin Broom

 

 

Colin Broom

 

 

Chief Executive Officer

 

 

Date: November 22, 2016

 

2



 

EXHIBIT INDEX

 

Exhibit
Number

 

Description

99.1

 

Press Release dated November 22, 2016

 

3


1 Year Nabriva Therapeutics Chart

1 Year Nabriva Therapeutics Chart

1 Month Nabriva Therapeutics Chart

1 Month Nabriva Therapeutics Chart

Your Recent History

Delayed Upgrade Clock